The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 17, 2017
Filed:
Sep. 05, 2012
Sung Youb Jung, Suwon-si, KR;
Young Eun Woo, Daejeon, KR;
SE Young Lim, Gunsan-si, KR;
IN Young Choi, Yongin-si, KR;
Jae Ho Lee, Seoul, KR;
SE Chang Kwon, Seoul, KR;
Sung Hwan Moon, Suwon-si, KR;
Jiawang Liu, Beijing, CN;
Sung Youb Jung, Suwon-si, KR;
Young Eun Woo, Daejeon, KR;
Se Young Lim, Gunsan-si, KR;
In Young Choi, Yongin-si, KR;
Jae Ho Lee, Seoul, KR;
Se Chang Kwon, Seoul, KR;
Sung Hwan Moon, Suwon-si, KR;
Jiawang Liu, Beijing, CN;
HANMI SCIENCE CO., LTD., Hwaseong-si, KR;
BEIJING HANMI PHARMACEUTICAL CO., LTD., Beijing, CN;
Abstract
A method for preventing or treating a cancer includes administering an anti-cancer pharmaceutical composition including an interferon alpha or a polymer conjugate thereof. The pharmaceutical composition can be co-administered with anti-cancer agents. The interferon alpha conjugate shows a longer in vivo half-life and a more excellent anti-cancer activity than the conventional interferon alpha, and in particular, its co-administration with an anti-cancer agent such as gemcitabine has synergistic inhibitory effects on cancer cell growth and proliferation so as to exhibit a remarkably excellent anti-cancer activity. Further, the anti-cancer pharmaceutical composition has excellent in vivo half-life and anti-cancer activity to greatly reduce administration frequency. Co-administration of an anti-cancer agent and the interferon alpha conjugate having excellent anti-cancer activity reduces administration dose of anti-cancer agent so as to reduce side effects of anti-cancer agent and increase treatment compliance of patient.